Browse By Region
Browse By Category
Recent News
By Category: Research
BARDA Funds Countermeasure for Burkholderia Infections
(Global Biodefense) A new drug to help protect the public against two bioterrorism threats and provide a new option to treat antibiotic-resistant infections will advance in development under a public-private partnership, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced this week.
- February 6, 2014
- | Filed under North America, Bioterrorism, and Research
Bioterrorism, Antibiotic-Resistant Bacteria To Be Aided By Carbavance Drug Candidate; HHS Partners With Rempex Pharmaceuticals, Funds Study
- February 6, 2014
- | Filed under Biotechnology and Research
Elusys Completes Enrollment in Three Phase 3 Safety Studies
(PR Newswire) Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability Read More »
- February 6, 2014
- | Filed under Agents & Toxins and Research
Bioterrorism, Antibiotic-Resistant Bacteria To Be Aided By Carbavance Drug Candidate
(Medical Daily) A new drug may help the U.S. government protect the homeland from a hypothetical bioterrorist threat or something we know is actually trying to kill us: drug-resistant bacteria threatening to undo a century of medical progress.The Department of Health and Human Services on Tuesday announced a five-year public-private partnership with Rempex Pharmaceuticals, of Read More »
- February 6, 2014
- | Filed under Agents & Toxins and Research